# 4310 @CRCTU logo AWPaediatric Cancer

## Brain

### In Development

|  |  |
| --- | --- |
| **CPT**: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients with Choroid Plexus Tumors (CPT-SIOP-2009) | [cptsiop2009@trials.bham.ac.uk](mailto:cptsiop2009@trials.bham.ac.uk) |
| **SIOP** Ependymoma II; An International Multi Centre Clinical Program for the diagnosis and treatment of children, adolescents and young adults with Ependymoma | [ependymoma@trials.bham.ac.uk](mailto:ependymoma@trials.bham.ac.uk) |
| **PNET5**: An international prospective study on clinically standard-risk medulloblastoma in children with low-risk biological profile (PNET5 MB-LR) or average-risk biological profile (PNET5 MB-SR) | [pnet5@trials.bham.ac.uk](mailto:pnet5@trials.bham.ac.uk) |
| **VINILO**: Phase I-II Study of Vinblastine in Combination with Nilotinib in Children, Adolescents and Young Adults with Refractory or Recurrent Low-Grade Glioma. | [vinilo@trials.bham.ac.uk](mailto:vinilo@trials.bham.ac.uk) |
| **INTREPID**: A phase I dose escalation study of intrathecal Etoposide as a continuous infusion investigating duration and rate of infusion in patients with leptomeningeal metastatic brain cancer | [intrepid@trials.bham.ac.uk](mailto:intrepid@trials.bham.ac.uk) |

## Germ Cell

### Open

|  |  |
| --- | --- |
| **SIOP CNS GCT II**: Prospective trial for the diagnosis and treatment of children, adolescents and young adults with intracranial germ cell tumours | [siopcnsgctii@trials.bham.ac.uk](mailto:siopcnsgctii@trials.bham.ac.uk) |

## Embryonic Tumour

### Open

|  |  |  |  |
| --- | --- | --- | --- |
| **HRNBL**: High risk neuroblastoma study 1 of SIOP- Europe (SIOPEN) | | [hrnbl@trials.bham.ac.uk](mailto:hrnbl@trials.bham.ac.uk) | |
| **LuDO**: A phase IIa study of 177Lutetium dotatate in children with primary refractory or relapsed high risk neuroblastoma. | | [ludo@trials.bham.ac.uk](mailto:ludo@trials.bham.ac.uk) | |
| **GD2**: A Phase I/II dose schedule finding study of CH14.18/CHO continuous infusion combined with subcutaneous aldesleukin (IL-2) in patients with primary refractory or relapsed neuroblastoma | | [gd2@trials.bham.ac.uk](mailto:gd2@trials.bham.ac.uk) | |
| **BEACON**: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma - BEACON-Neuroblastoma Trial | | [beacon@trials.ac.uk](mailto:beacon@trials.ac.uk) | |
| **IMAT**: A randomised phase I/II study of intensity modulated arc therapy techniques in abdominal  neuroblastoma | imat@trials.bham.ac.uk | |

## Haematology Malignancies

### Open

|  |  |  |
| --- | --- | --- |
| **EuroNet PHL-LP1:** First International Inter-Group Study for Nodular Lymphocyte Predominant Hodgkin’s Lymphoma in Children and Adolescents | [euronetphl-lp1@trials.bham.ac.uk](mailto:euronetphl-lp1@trials.bham.ac.uk) | |
| **Interfant 06**: International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukaemia (LK 2006 10) | | [interfant06@trials.bham.ac.uk](mailto:interfant06@trials.bham.ac.uk) | |
| **UKALL 2011**: United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011 | [ukall2011@trials.bham.ac.uk](mailto:ukall2011@trials.bham.ac.uk) | |
| **Inter-B-NHL 2010**: Intergroup trial for children or adolescents with B-Cell NHL or B-AL: evaluation of rituximab efficacy and safety in high risk patients | [interbnhl@trials.bham.ac.uk](mailto:interbnhl@trials.bham.ac.uk) | |

### In Development

|  |  |
| --- | --- |
| **NECTAR**: A Phase I trial of NECTAR (Nelarabine, Etoposide and cyclophosphamide in T-ALL relapse): A joint study of TACL and POETIC | nectar@trials.bham.ac.uk |

## Histiocytosis

### In Development

|  |  |
| --- | --- |
| **LCH IV**: International collaborative treatment protocol for children and adolescents with langerhans cell histiocytosis | [lchiv@trials.bham.ac.uk](mailto:lchiv@trials.bham.ac.uk) |

## Liver

### Open

|  |  |
| --- | --- |
| **SIOPEL 6**: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate in reducing ototoxicity in patients receiving cisplatin chemotherapy for standard risk hepatoblastoma | [siopel6@trials.bham.ac.uk](mailto:siopel6@trials.bham.ac.uk) |

## Sarcoma

### Open

|  |  |
| --- | --- |
| **RMS 2005**: A protocol for non-metastatic rhabdomyosarcoma (STS 2006 04) | [rms2005@trials.bham.ac.uk](mailto:rms2005@trials.bham.ac.uk) |
| **VIT0910**: International randomised phase II trial of the combination of Vincristine and Irinotecan with or without Temozolomide (VI or VIT) in patients with refractory or relapsed Rhabdomyosarcoma | [vit0910@trials.bham.ac.uk](mailto:vit0910@trials.bham.ac.uk) |
| **EE2012**: International randomised controlled trial for the treatment of newly diagnosed Ewing's sarcoma family of tumours | [eex2012@trials.bham.ac.uk](mailto:eex2012@trials.bham.ac.uk) |

### In Development

|  |  |
| --- | --- |
| **rEECur**: International Randomised Controlled Trial of Chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma | [reecur@trials.bham.ac.uk](mailto:reecur@trials.bham.ac.uk) |

# Adult Cancer

## Bladder

### Open

|  |  |
| --- | --- |
| **TUXEDO**: Phase I/II feasibility study of cetuximab with 5FU and Mitomycin C or cisplatin with concurrent radiotherapy in muscle invasive bladder cancer | [tuxedo@trials.bham.ac.uk](mailto:tuxedo@trials.bham.ac.uk) |

## Breast

**In Development**

|  |  |
| --- | --- |
| **LORIS**: Can patients with newly diagnosed low-grade DCIS safely avoid surgery, without detriment to their psychological well-being and can those patients who require surgery be identified by pathological and radiological criteria? | [loris@trials.bham.ac.uk](mailto:loris@trials.bham.ac.uk) |
| **ROSCO**: Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer | [rosco@trials.bham.ac.uk](mailto:rosco@trials.bham.ac.uk) |

## Haematological Malignancies

### Open

|  |  |
| --- | --- |
| **BaP Pilot**: Single Arm Phase II trial assessing the efficacy, compliance and safety of Bezafibrate and medroxyProgesterone acetate (BaP) as non-toxic therapy against myeloid and lymphoid cancers. | [bap@trials.bham.ac.uk](mailto:bap@trials.bham.ac.uk) |
| **CyCLLe**: An early phase II trial of Cyclosporin A in early adverse risk CLL | [cyclle@trials.bham.ac.uk](mailto:cyclle@trials.bham.ac.uk) |
| **De-Iron**: A phase II study of the efficacy and safety of Deferasirox administered at early iron loading in patients with transfusion-dependent Myelodysplastic Syndromes | [de-iron@trials.bham.ac.uk](mailto:de-iron@trials.bham.ac.uk) |
| **HA-1**: A phase I clinical trial of the vaccination of healthy human volunteers against the minor histocompatibility antigen (mHAg) HA-1 using a DNA and MVA ‘prime/boost’ regimen | [ha1@trials.bham.ac.uk](mailto:ha1@trials.bham.ac.uk) |
| **LenaRIC**: Phase II study of the adjunctive use of lenalidomide in patients undergoing reduced intensity conditioning allogeneic transplantation for multiple myeloma | [lenaric@trials.bham.ac.uk](mailto:lenaric@trials.bham.ac.uk) |
| **FIGARO**: A Randomised Trial of the FLAMSA-BU Conditioning Regimen in Patients with Acute Myeloid Leukaemia and Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation | [figaro@trials.bham.ac.uk](mailto:figaro@trials.bham.ac.uk) |
| **MAJIC**: A phase II study of Ruxolitinib (INCB424) in patients with High Risk Polycythaemia Vera or Essential Thrombocythaemia resistant to or intolerant of standard therapy | [majic@trials.bham.ac.uk](mailto:majic@trials.bham.ac.uk) |
| **PICLLe**: Phase I/II clinical trial to assess the efficacy and safety of olaparib, a PARP-inhibitor, in relapsed and refractory chronic lymphocytic leukaemia patients with an 11q deletion or ATM mutation and relapsed/refractory patients with T-prolymphocytic leukaemia and mantle cell lymphoma | [piclle@trials.bham.ac.uk](mailto:piclle@trials.bham.ac.uk) | |
| **RAvVA**: A Randomised Phase II Trial of 5-Azacitidine versus Vorinostat in Combination with 5-Azacitidine in patients with Newly Diagnosed, Relapsed or Refractory Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome ineligible for intensive chemotherapy | [ravva@trials.bham.ac.uk](mailto:ravva@trials.bham.ac.uk) | |
| **ROMAZA**: Phase I trial of Romidepsin plus Azacitidine combination therapy in patients with newly diagnosed, relapsed or refractory Acute Myeloid Leukaemia ineligible for salvage chemotherapy | [romaza@trials.bham.ac.uk](mailto:romaza@trials.bham.ac.uk) | |
| **BREVITY**: A phase II study of brentuximab vedotin (SGN-35) using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity | [brevity@trials.bham.ac.uk](mailto:brevity@trials.bham.ac.uk) | |
| **IcICLLe**: Assessment of the mechanism of action of PCI-32765 in B-cell receptor pathway inhibition in CLL | [iciclle@trials.bham.ac.uk](mailto:iciclle@trials.bham.ac.uk) | |
| **Viola**: A Phase I Trial of Combined Azacitidine and Lenalidomide Salvage Therapy in Patients with Acute Myeloid Leukaemia who Relapse after Allogeneic Stem Cell Transplantation | [viola@trials.bham.ac.uk](mailto:viola@trials.bham.ac.uk) | |

### In Development

|  |  |
| --- | --- |
| **CALiBRe**: Assessment of the mechanism of action of CAL-101 in B-cell receptor pathway inhibition in CLL | [calibre@trials.bham.ac.uk](mailto:calibre@trials.bham.ac.uk) |
| **ElAstic**: A phase Ib study of Eltrombopag and Azacitidine in patients with high risk myelodysplastic syndromes and related disorders | [elastic@trials.bham.ac.uk](mailto:elastic@trials.bham.ac.uk) |
| **Matchpoint**: MAnagement of Transformed CHronic myeloid leukaemia: POnatinib and INTensive chemotherapy: a dose-finding study | [matchpoint@trials.bham.ac.uk](mailto:matchpoint@trials.bham.ac.uk) |
| **RomiCar**: Phase I/II study to determine the maximum tolerated dose and overall response rate of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma | [romicar@trials.bham.ac.uk](mailto:romicar@trials.bham.ac.uk) |
| **TIER**: A Phase I/II Study of Thiotepa, Ifosphamide, Etoposide and Rituximab for the treatment of relapsed and refractory primary central nervous system lymphoma | tier@trials.bham.ac.uk |
| **PHAZAR**: A phase Ib study to assess the safety and tolerability of oral Ruxolitinib in combination with 5-azacitidine in patients with accelerated phase myeloproliferative neoplasms, myelodysplastic syndromes(MDS) or acute myeloid leukaemia (AML) | phazar@trials.bham.ac.uk |

## Head and Neck

### Open

|  |  |
| --- | --- |
| **ArChIMEDEs Op**: Accelerated Hypofractionation, Chemotherapy, Intensity Modulation and Evaluation of Dose Escalation in Oropharyngeal Cancer | [archimedes-op@trials.bham.ac.uk](mailto:archimedes-op@trials.bham.ac.uk) |
| **OROMOUTH**: HPV prevalence in the mouth and oropharynx of the tonsillectomy population. | [oromouth@trials.bham.ac.uk](mailto:oromouth@trials.bham.ac.uk) |
| **MVA**: A Cancer Research UK Phase Ib trial to determine the safety, tolerability and immunogenicity of extended schedule vaccination with MVA-EBNA1/LMP2 in patients with Epstein Barr Virus positive nasopharyngeal carcinoma | [can-crctu-edd@adf.bham.ac.uk](mailto:can-crctu-edd@adf.bham.ac.uk) |

### In Development

|  |  |
| --- | --- |
| **PACiFiC**: Phase Ib trial of Atu027 in Combination with Cisplatin, 5-FU and Cetuximab in Patients with Head and Neck Cancer | [pacific@trials.bham.ac.uk](mailto:pacific@trials.bham.ac.uk) |
| **CompARE**: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer | [compare@trials.bham.ac.uk](mailto:compare@trials.bham.ac.uk) |

## Hepatocellular Carcinoma

### Open

|  |  |
| --- | --- |
| **BILCAP**: A randomised clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following surgery for biliary tract cancer | [bilcap@trials.bham.ac.uk](mailto:bilcap@trials.bham.ac.uk) |
| **TACE-2**: A randomised placebo-controlled, double-blinded, phase III trial of sorafenib in combination with transarterial chemoembolisation in hepatocellular cancer | [tace2@trials.bham.ac.uk](mailto:tace2@trials.bham.ac.uk) |

### In Development

|  |  |
| --- | --- |
| **IMMUNOTACE**: A phase II randomised clinical trial of conditioning cyclophosphamide and chemoembolisation with or without vaccination with Dendritic Cells pulsed with HepG2 lysate in vivo in patients with Hepatocellular Carcinoma | [immunotace@trials.bham.ac.uk](mailto:immunotace@trials.bham.ac.uk) |
| **ACTICCA-1**: Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma | [bilcap@trials.bham.ac.uk](mailto:bilcap@trials.bham.ac.uk) |

## Lung

### Open

|  |  |
| --- | --- |
| **STOMP**: A randomised phase II study of AZD2281 maintenance treatment in patients with chemosensitive small cell lung cancer | [stomp@trials.bham.ac.uk](mailto:stomp@trials.bham.ac.uk) |

### In Development

|  |  |
| --- | --- |
| **SPECIAL**: Standard or PalliativE Care In Advanced Lung cancer. Does early referral of patients with metastatic non-small cell lung cancer to UK specialist palliative care services make a difference in their quality of life or survival? | [special@trials.bham.ac.uk](mailto:special@trials.bham.ac.uk) |
| **National Lung Matrix**: Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer | lungmatrix@trials.bham.ac.uk |
| **RUXSAC**: A double blind, placebo-controlled, randomised phase II study of Pemetrexed and Cisplatin with and without Ruxolitinib in Malignant Pleural Mesothelioma | ruxsac@trials.bham.ac.uk |

## Prostate

### Open

|  |  |
| --- | --- |
| **AdUP**: A Phase I Clinical Trial of a replication defective type 5 adenovirus vector expressing nitroreductase and GMCSF (AdNRGM) given via trans-perineal, template-guided, intra-prostatic injection, followed by intravenous CB1954, in patients with locally relapsed hormone-refractory Prostate Cancer. | [adup@trials.bham.ac.uk](mailto:adup@trials.bham.ac.uk) |

|  |  |
| --- | --- |
| **CANTATA**: A multicentre phase II randomised controlled trial evaluating cabazitaxel versus docetaxel re-challenge for the treatment of metastatic castrate refractory prostate cancer, previously treated with docetaxel at inception of primary hormone therapy | [cantata@trials.bham.ac.uk](mailto:cantata@trials.bham.ac.uk) |

## Renal

### Open

|  |  |
| --- | --- |
| **PAZ02**: A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and Performance Status 2 (ECOG) | [pazo2@trials.bham.ac.uk](mailto:pazo2@trials.bham.ac.uk) |
| **ADIUVO**: Efficacy of adjuvant mitotane treatment in prolonging recurrence-free survival in patients with adrenocortical carcinoma at low-intermediate risk of recurrence | [adiuvo@trials.bham.ac.uk](mailto:adiuvo@trials.bham.ac.uk) |

## Sarcoma

### Open

|  |  |
| --- | --- |
| **Axi-STS**: A clinicopathological phase II study of axitinib in patients with advanced angiosarcoma and other soft tissue sarcomas | [axi-sts@trials.bham.ac.uk](mailto:axi-sts@trials.bham.ac.uk) |
| **SCART**: Phase I/II study of oral MEK inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination with Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposi’s sarcoma (KS). | [scart@contacts.bham.ac.uk](mailto:scart@contacts.bham.ac.uk) |

## Skin

### Open

|  |  |
| --- | --- |
| **UKMCC-01**: A phase II study of pazopanib in metastatic merkel cell carcinoma | [ukmcc-01@trials.bham.ac.uk](mailto:ukmcc-01@trials.bham.ac.uk) |

### In Development

|  |  |
| --- | --- |
| **SPOT**: Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments (SPOT): a feasibility study | [spot@trials.bham.ac.uk](mailto:spot@trials.bham.ac.uk) |

## Gynaecology

### Open

|  |  |
| --- | --- |
| **DESKTOP III**: A randomized multicentre study to compare the efficacy of additional tumour de-bulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer | [desktopIII@trials.bham.ac.uk](mailto:desktopIII@trials.bham.ac.uk) |

### In Development

|  |  |
| --- | --- |
| **EPIVIN**: Phase II clinical trial investigating the use of epigallocatechin-3-gallate (Veregen) in the treatment of vulval intraepithelial neoplasia | [epivin@trials.bham.ac.uk](mailto:epivin@trials.bham.ac.uk) |

# Paediatric Non-Cancer

## Disease Prevention

### Open

|  |  |
| --- | --- |
| ***PEP*talk 2**: Pilot of a randomised controlled trial to compare VZIG and aciclovir as post-exposure prophylaxis against chickenpox in children with cancer | [peptalk2@trials.bham.ac.uk](mailto:peptalk2@trials.bham.ac.uk) |

# Adult Non-Cancer

## Liver

### Open

|  |  |
| --- | --- |
| **REALISTIC**: A multicentre, phase II, open label, randomised controlled trial of repeated autologous infusions of g-CSF mobilised CD133+ bone marrow stem cells in patients with cirrhosis | [realistic@trials.bham.ac.uk](mailto:realistic@trials.bham.ac.uk) |

### In Development

|  |  |
| --- | --- |
| **BUTEO:** A Single arm, Two-stage, Multi-centre, Phase II clinical trial investigating the safety and activity of the use of BTT1023, a vascular adhesion protein (Vap-1) in the treatment of patients with Primary Sclerosing Cholangitis (PSC) | buteo[@trials.bham.ac.uk](mailto:BUTEO@trials.bham.ac.uk) |

## Supportive Care

### In Development

|  |  |
| --- | --- |
| **FOAM**: Folic acid supplementation in the management of menopausal symptoms in cancer survivors and healthy postmenopausal women | [foam@trials.bham.ac.uk](mailto:foam@trials.bham.ac.uk) |